These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32187452)

  • 1. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
    Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
    Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes in Patients with Multi-Hit
    Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
    Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Kittai AS; Miller C; Goldstein D; Huang Y; Abruzzo LV; Beckwith K; Bhat SA; Bond DA; Grever MR; Heerema NA; Rogers KA; Ruppert AS; Byrd JC; Woyach JA
    Blood; 2021 Dec; 138(23):2372-2382. PubMed ID: 34314481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE
    Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Visentin A; Mauro FR; Cibien F; Vitale C; Reda G; Fresa A; Ciolli S; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Scarfò L; Sportoletti P; Pravato S; Piazza F; Coscia M; Laurenti L; Molica S; Foà R; Cuneo A; Trentin L
    Am J Hematol; 2022 Mar; 97(3):E95-E99. PubMed ID: 34904743
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
    Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.